The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation

Neuropharmacology

Volumn 39, Issue 6, 2000, Pages 1016-1020

  Boireau, A ^a   Dubedat, P ^a   Bordier, F ^a   Imperato, A ^a   Moussaoui, S ^a  

^a SANOFI   (France)

Author keywords

Dopamine; MPP+; MPTP; Parkinson's disease; Riluzole

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 7 NITROINDAZOLE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; RILUZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; KINETICS; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; INDAZOLES; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE, SECONDARY; RILUZOLE;

EID: 0034056425     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00188-4     Document Type: Article

References (30)

1. Benazzouz A., Boraud T., Dubedat P., Boireau A., Stutzmann J.-M., Gross C. Rituzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. European Journal of Pharmacology. 284:1995;299-307.
2. Bensimon G., Lacomblez L., Meininger V., Group A.R.S. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl. J. Med. 330:1994;585-591.
3. Boireau A., Dubédat P., Bordier F., Peny C., Miquet J.M., Durand G., Meunier M., Doble A. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport. 5:1994;2657-2660.
4. +-induced increase in striatal extracellular dopamine in rats in vivo. Neuroreport. 5:1994;2157-2160.
5. Boireau A., Bordier F., Dubédat P., Pény C., Impérato A. Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. Neuroscience Letters. 234:1997;123-126.
6. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.J., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proceedings of the National Academy of Sciences. 80:1983;4546-4550.
7. Castagnoli K., Palmer S., Anderson A., Bueters T., Castagnoli N. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalized oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem. Res. Toxicol. 10:1997;364-368.
8. Cheramy A., Barbeito L., Godeheu G., Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neuroscience Letters. 147:1992;209-212.
9. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Beichert C.M., Kopin I.J. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatr. Res. 1:1979;249-254.
10. Debono M.W., Le Guem J., Canton T., Doble A., Pradier L. Inhibition by riluzole of electrophysiological response mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. European Journal of Pharmacology. 235:1993;283-289.
11. Di Monte D.A., Royland J.E., Anderson A., Castagnoli K., Castagnoli N., Langston J.W. Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity. Journal of Neurochemistry. 69:1997;1771-1773.
12. Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 47:1996;S233-241.
13. Guyot M.C., Palfi S., Stutzmann J.M., Maziere M., Hantraye P., Brouillet E. Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience. 81:1997;141-149.
14. Hantraye P., Brouillet E., Ferrante R., Palfi S., Dolan R., Matthews R.T., Beal M.F. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nature Med. 2:1996;1017-1021.
15. Hebert T., Drapeau P., Pradier L., Dunn R.J. Block of the rat brain IIA sodium channel α subunit by the neuroprotective drug riluzole. Molecular Pharmacology. 45:1994;1055-1060.
16. Hétier E., Boireau A., Dubédat P., Blanchard J.-C. Neurotensin effects on evoked release of dopamine in slices from striatum, nucleus accumbens and prefrontal cortex in rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 337:1988;13-17.
17. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explains selective toxicity. Proceedings of the National Academy of Sciences of the U.S.A. 82:1985;2173-2177.
18. Jones-Humble S.A., Morgan P.F., Cooper B.R. The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP model of Parkinson's disease. Life Sciences. 54:1994;245-252.
19. Kopin I.J. Mechanisms of 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine induced destruction of dopaminergic neurons. Herken H., Hucho F. Selective Neurotoxicity, vol. 102. 1992;333-356 Springer-Verlag, Berlin.
20. Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 347:1996;1425-1431.
21. Langston J.W., Ballard P.A., Tetrud J.W., Irwin I.J. Chronic parkinsonism in humans due to a product of mepiridine analog synthesis. Science. 219:1983;979-980.
22. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A. lntraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 311:1984;464-467.
23. Martin D., Thompson M.A., Nadler J.V. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. European Journal of Pharmacology. 250:1993;473-476.
24. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sciences. 36:1985;2503-2508.
25. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proceedings of the National Academy of Sciences. 93:1996;4565-4571.
26. Samuel D., Blin O., Dusticier N., Nieoullon A. Effects of riluzole (2-amino-6-trifluoromethoxy benzothiazole) on striatal neurochemical markers in the rat, with special reference to the dopamine, choline, GABA and glutamate synaptosomal high affinity uptake systems. Fundam. Clin. Phamacol. 6:1992;177-184.
27. Schultz J.B., Matthews R.T., Muqit M.M.K., Browne S.E., Beal F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. Journal of Neurochemistry. 64:1995;936-939.
28. +-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. Neuroreport. 5:1994;2598-2600.
29. Stutzmann J.M., Doble A. Blockade of glutamatergic transmission and neuroprotection: the strange case of riluzole. Jolles G., Stutzmann J.M. Neurodegenerative Diseases. 1994;205-214 Academic Press Ltd, London.
30. Urenjak J., Obrenovitch T.P. Pharmacological modulation of sodium channels by riluzole: an alternative to antiexcitotoxic actions. Rev. Contemp. Pharmacother. 8:1997;237-246.